focus -WSS

focus

author：explore 2025-09-28 02:28:57 - browse：254

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

WSS

PBM executives asked to testify by House panel

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Lawmakers grill UnitedHealth CEO on Change cyberattack

JPM pitch from hospitals? Revenue streams outside of patient care

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Can gargling with Listerine treat gonorrhea of the mouth?

Wikipedia

focus

knowledge

At least 13 dead in Texas as scorching temps continue

Has Bernie Sanders reached the limit of his pharma bullying effort?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hospital chaplains balance Covid safety with patients’ spiritual needs

What does generative AI mean for health care? We asked experts

Is it ever OK for doctors to lie to their patients?

Continuity nursing helped my family in our darkest PICU moments

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Wikipedia

Boston Scientific acquires urology company Axonics for $3.7 billion

At JPM 2024, hospital systems pitch financial strength to investors

Ascension's ugly legal battle over care for poor patients in Texas

Chemotherapy before breast cancer surgery might fuel metastasis

Brain technologies pose threats that are all too real, experts warn

In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

knowledge

knowledge

entertainment